BRU · ARGX.BR
argenx SE
€804.40+€7.80 (+0.98%)
argenx SE’s quoted price sits in the upper half of its reported 52-week range, 13.04% below the high.
Loading market information…
AMS · LKFT.AS · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Lakefront Biotherapeutics’s quoted price sits in the upper half of its reported 52-week range, 5.92% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Lakefront Biotherapeutics’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -€0.70. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Lakefront Biotherapeutics’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:54 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 23, 2025 | -€2.33-1,126.32% vs estimate | €74.98M+8.91% vs estimate |
|---|
| Q4 2024 | Feb 12, 2025 | €0.38+155.07% vs estimate | €75.50M+8.0% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | -€0.77-57.14% vs estimate | €59.85M-17.07% vs estimate |
|---|
THE ANALYST VIEW
23 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€804.40+€7.80 (+0.98%)
argenx SE’s quoted price sits in the upper half of its reported 52-week range, 13.04% below the high.
€32.52-€0.24 (-0.73%)
Koninklijke Ahold Delhaize N.V.’s quoted price sits in the lower half of its reported 52-week range, 23.55% below the high.
€1.08-€0.01 (-0.69%)
Pharming Group N.V.’s quoted price sits in the lower half of its reported 52-week range, 40.6% below the high.
€6.49-€0.07 (-1.07%)
Barco N.V.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$20.86+$0.29 (+1.41%)
Assembly Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.47% below the high.
$1.11-$0.06 (-5.13%)
Spero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.96% below the high.
$6.83+$0.04 (+0.52%)
Instil Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.5% below the high.
$6.53+$0.19 (+2.92%)
NextCure, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.55% below the high.
